Nabi scores $540M pact for NicVAX; Kansas University gets vaccine research contract;
> Nabi Biopharmaceuticals has wrapped a licensing deal worth potentially more than $540 million with GlaxoSmithKline for its experimental therapy designed to treat nicotine addiction and prevent smokers who kick the habit from tearing open a fresh pack. Report
The Associated Press details the metoric rise of the vaccine business in recent years, from the days when vaccine research was all but abaondon to the coming golden era of groundbreaking therapies. Report
The National Institutes of Health's National Institute for Allergy and Infectious Disease has granted Kansas University a five-year, $6.85 million research contract to help study how to boost the effectiveness and safety of infectious disease vaccines. Report
And Finally... Vets are suggesting that some dogs get the H3N8--a horse virus that jumped to canines about five years ago. Report
Comments
Post new comment
Paid Research Reports
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession
- Optimizing Lifecycle Management: Maximizing commercial lifespan through label expansion and combination products
- The CRO Market Outlook: Emerging markets, leading players and future trends
- Pharmaceutical Sales Force Effectiveness Strategies
- Commercial Insight: Influenza Vaccines and Antivirals - The pandemic's long-term impact
